Investigator meeting · Dr. Chloé Xu

06 Sept 2026 · In person · Dr. Chloé Xu, Gustave Roussy · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0100—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Sequencing after progression
Elderly / ECOG 2 patients

Scientific content used

irAE management guide
VTX core scientific deck v3.2

Questions raised

No questions recorded.

Notes

Investigator meeting with oncology pharmacist at Gustave Roussy. Discussed brain-metastasis subgroup data, sequencing after progression, elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0100

Audit history (0)

All create, update and approval events for this record

No audit events in sample data